CHRS

1.67

3.47% -0.06

Handel nachbörslich: 1.75 0.08 +4.79%

Coherus Oncology Inc (CHRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CHRS? Forum Prognose

Schlusskurs vom Vortag:

$1.73

Offen:

$1.73

24-Stunden-Volumen:

620.54K

Relative Volume:

0.29

Marktkapitalisierung:

$250.32M

Einnahmen:

$42.17M

Nettoeinkommen (Verlust:

$-183.12M

KGV:

-1.1468

EPS:

-1.4562

Netto-Cashflow:

$-138.51M

1W Leistung:

+4.37%

1M Leistung:

-8.24%

6M Leistung:

-1.76%

1J Leistung:

+113.61%

1-Tages-Spanne:

$1.66

$1.785

1-Wochen-Bereich:

$1.63

$1.79

52-Wochen-Spanne:

$0.71

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Firmenname

Coherus Oncology Inc

Sektor

Healthcare (1116)

Branche

Biotechnology (624)

Telefon

(650) 649-3530

Adresse

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Mitarbeiter

147

Twitter

@coherus_bio

Nächster Verdiensttermin

2025-03-10

Neueste SEC-Einreichungen

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CHRS Coherus Oncology Inc	1.67	259.31M	42.17M	-183.12M	-138.51M	-1.4562
VRTX Vertex Pharmaceuticals Inc	434.30	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	763.04	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	748.25	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.34	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.81	35.01B	606.42M	-1.28B	-997.58M	-6.403

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-23	Eingeleitet	Oppenheimer	Outperform
2025-09-04	Hochstufung	Maxim Group	Hold → Buy
2024-08-16	Herabstufung	UBS	Buy → Neutral
2023-11-17	Eingeleitet	Robert W. Baird	Outperform
2023-11-08	Herabstufung	Maxim Group	Buy → Hold
2023-07-24	Eingeleitet	Citigroup	Buy
2023-05-01	Eingeleitet	Truist	Buy
2023-03-28	Hochstufung	UBS	Neutral → Buy
2022-06-14	Eingeleitet	UBS	Neutral
2022-03-07	Herabstufung	JP Morgan	Overweight → Neutral
2020-07-16	Eingeleitet	BofA Securities	Neutral
2020-04-17	Eingeleitet	SunTrust	Buy
2019-08-13	Eingeleitet	Mizuho	Buy
2019-08-02	Bestätigt	H.C. Wainwright	Buy
2019-08-02	Bestätigt	Maxim Group	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-07	Eingeleitet	H.C. Wainwright	Buy
2018-08-28	Eingeleitet	H.C. Wainwright	Buy
2018-03-09	Bestätigt	Maxim Group	Buy
2017-08-08	Bestätigt	JP Morgan	Overweight
2017-06-13	Bestätigt	Maxim Group	Buy
2017-05-05	Eingeleitet	BMO Capital Markets	Outperform
2016-10-19	Eingeleitet	Robert W. Baird	Outperform
2016-09-07	Eingeleitet	Maxim Group	Buy
2016-07-27	Eingeleitet	Citigroup	Buy
2016-01-20	Eingeleitet	Credit Suisse	Outperform

Alle ansehen

Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten

05:13 AM

Coherus Biosciences (CHRS) is one of the best penny stocks, here is why - MSN

05:13 AM

Apr 02, 2026

Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - marketbeat.com

Apr 02, 2026

Apr 01, 2026

Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk - Yahoo Finance

Apr 01, 2026

Mar 31, 2026

Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why - Yahoo Finance

Mar 31, 2026

Mar 27, 2026

Coherus Oncology (CHRS) upgraded to buy: Here's what you should know - msn.com

Mar 27, 2026

Mar 26, 2026

Vanguard disaggregates holdings; 0% stake in Coherus (NASDAQ: CHRS) - Stock Titan

Mar 26, 2026

If You Invested $1,000 in Coherus (CHRS) - stocktitan.net

Mar 26, 2026

Mar 25, 2026

Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline - openpr.com

Mar 25, 2026

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 25, 2026

Mar 24, 2026

Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Mar 24, 2026

Mar 19, 2026

Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat

Mar 16, 2026

Mar 14, 2026

Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat

Mar 14, 2026

Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat

Mar 14, 2026

Mar 13, 2026

Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Mar 13, 2026

Mar 11, 2026

Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN

Mar 11, 2026

Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - simplywall.st

Mar 11, 2026

Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN

Mar 11, 2026

Mar 10, 2026

Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada

Mar 10, 2026

CHRS: Rapid oncology pipeline progress and strong LOQTORZI sales drive growth and pivotal trial plans - TradingView

Mar 10, 2026

Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart

Mar 10, 2026

Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com India

Mar 10, 2026

Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com

Mar 10, 2026

Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart

Mar 10, 2026